<< Report on the wounds or wound dressing drug pipeline | ABC News should focus more on integrity, says National Center for Public Policy Research >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Ελληνικά | हिन्दी | Русский | Svenska | Polski

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Published on December 18, 2009 at 8:28 AM · No Comments

Celgene Corporation (Nasdaq:CELG) today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB). The investigational study evaluated REVLIMID^® compared to placebo in multiple myeloma patients following autologous stem cell transplant, and the independent Data and Safety Monitoring Board reported that the trial had met its primary endpoint of a statistically significant improvement in time to disease progression. The study was sponsored by the NCI under a Clinical Trials Agreement with Celgene.

Further results from the study will be presented in a peer-reviewed setting in 2010.

Source Celgene Corporation

0c6a54e6-8de2-47b0-aae9-abc202ee4ec9|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Arthralgia, Back Pain, Bone, Bone Marrow, Cancer, Cell, Constipation, Cough, Dialysis, Diarrhea, Dyspnea, Edema, Headache, Hyperglycemia, Hypersensitivity, Insomnia, Leukemia, Multiple Myeloma, Myeloma, Nausea, Neutropenia, Nursing, Placebo, Pregnancy, Pulmonary Embolism, Stem Cell, Thalidomide, Thrombocytopenia, Thrombosis, Transplant

Related posts

Novel imaging technique reveals new visual resolution of NK cell actionScientists reveal in more detail than ever before how white blood cells kill diseased tissue using d...
BancoVida, CBAI partner to offer umbilical cord blood collection services in Puerto RicoCord Blood America, Inc. announced today it has entered into an agreement with BancoVida to offer um...
Childhood cancer survivors may face high risk of late GI complications after therapyPatients who received therapy for cancer during childhood have an increased risk of developing gastr...
Research on patients' immune system may lead to new diagnostic tool for HIV treatmentMayo Clinic researchers have shown why, in a minority of HIV patients, immune function improves desp...
VYTORIN reduces major vascular events in patients with chronic kidney diseaseIn a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/...
sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 DiabetesZealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of inno...
Study finds no benefit from self-management counseling in patients with heart failurePatients with mild to moderate heart failure who received educational materials and self-management ...
Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpointMerck today reported that two pivotal Phase III registration studies for boceprevir, its investigati...
Dyax launches newly enhanced product website featuring comprehensive financial assistance programDyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com...
Multiple presentations on nab-driven chemotherapy at 46th ASCOAbraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab...
Children and teens with moderate to severe OSA have lower academic grades: ResearchThe average academic grades of children and teens with moderate to severe obstructive sleep apnea ar...
Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myelomaArray BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its nove...
Genentech to present new data for targeted cancer medicines at 46th ASCOGenentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new ...
RSCRC scientists explore mysteries of human embryonic stem cellsAt Rutgers' Stem Cell Research Center scientists are exploring the mysteries of human embryonic stem...
Study demonstrates potential ability of Chronix serum DNA assays in diagnosis of breast cancerChronix Biomedical today announced publication of a study that supports the utility of its serum DNA...
Patient-safety incidents: 10% diedNearly one million patient-safety incidents occurred among Medicare patients over the years 2006, 20...
Hercules Technology Growth Capital commits over $52.0M in structured debt financingHercules Technology Growth Capital, Inc., the leading specialty finance company providing venture de...
People with varicose veins should seek professional consultationMarch is DVT Awareness Month and Vein Clinics of America encourages people with varicose veins, part...
Baxter International reports net income of $572M for the fourth-quarter of 2009Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and prov...
HTDS announces possible merger with EU-based, stem-cell research companyHard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica BioC...
Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myelomaOnyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 s...
Tibotec Therapeutics' INTELENCE granted FDA traditional approvalThe FDA granted traditional approval for INTELENCE® (etravirine) tablets, a non-nucleoside reverse t...
Genentech submits sBLAs to the FDA for AvastinGenentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitte...
Boron-based molecules can be used as new pharmacophoresChemists and biologists have successfully demonstrated that specially synthesized boron compounds ar...
New study set to change how critically ill patients are treatedThe current practice of intensively lowering blood glucose in critically ill patients increases the ...
Herbal medicines may help patients with gastrointestinal disordersHerbal medicines could benefit patients suffering from gastrointestinal (GI) motility disorders that...
Research suggests those who have chronic pain may need to assess vitamin D statusMayo Clinic research shows a correlation between inadequate vitamin D levels and the amount of narco...
New insights into development of the human immune systemA UCSF study has found that a surprisingly high number of maternal cells enters the fetus during pre...
Smoking during pregnancy and SIDSA new study provides the most direct evidence that there exists a causal link between smoking during...
FDA to stop the marketing of unapproved injectable colchicineThe U.S. Food and Drug Administration has announced its intention to take enforcement action against...
New study suggests Pioglitazone HCl may significantly improve key predictors of cardiovascular riskStudy results published in the May 17th issue of Circulation, the journal of the American Heart Asso...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.